In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile

<p>Abstract</p> <p>Background</p> <p>Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade.</p> <p>Methods</p> <p>As an alternat...

Full description

Bibliographic Details
Main Authors: Bronckers Antonius LJJ, Faber Chris, Stallmann Hein P, Nieuw Amerongen Arie V, Wuisman Paul IJM
Format: Article
Language:English
Published: BMC 2006-02-01
Series:BMC Musculoskeletal Disorders
Online Access:http://www.biomedcentral.com/1471-2474/7/18
Description
Summary:<p>Abstract</p> <p>Background</p> <p>Polymethyl-methacrylate (PMMA) beads releasing antibiotics are used extensively to treat osteomyelitis, but require surgical removal afterwards because they do not degrade.</p> <p>Methods</p> <p>As an alternative option, this report compares the <it>in vitro </it>gentamicin release profile from clinically used, biodegradable carrier-materials: six injectable cements and six granule-types. Cement cylinders and coated granules containing 3% gentamicin were submerged in dH<sub>2</sub>O and placed in a 48-sample parallel drug-release system. At regular intervals (30, 90, 180 min. and then every 24 h, for 21 days), the release fluid was exchanged and the gentamicin concentration was measured. The activity of released gentamicin was tested on <it>Staphylococcus aureus</it>.</p> <p>Results</p> <p>All combinations showed initial burst-release of active gentamicin, two cements had continuous-release (17 days). The relative release of all cements (36–85%) and granules (30–62%) was higher than previously reported for injectable PMMA-cements (up to 17%) and comparable to other biodegradable carriers. From the cements residual gentamicin could be extracted, whereas the granules released all gentamicin that had adhered to the surface.</p> <p>Conclusion</p> <p>The high release achieved shows great promise for clinical application of these biodegradable drug-carriers. Using the appropriate combination, the required release profile (burst or sustained) may be achieved.</p>
ISSN:1471-2474